Coronavirus Update: J&J Pauses COVID-19 Vaccine Trial After Unexplained Illness
Plus: China Starts Vaccines Pre-Order
J&J becomes the second company to pause a COVID-19 vaccine trial, releasing few details but emphasizing the measure's precautionary nature.
You may also be interested in...
Patient confidentiality and trial blinding precluded a Janssen official from sharing specifics about the safety event that led to a study enrollment pause, but Advisory Committee on Immunization Practices representatives say the lack of detailed, publicly disclosed information is not helping vaccine confidence.
NIH study of monoclonal antibody therapy in combination with Gilead's remdesivir paused for safety reasons.
It will be several days at least before more information is available about the unexpected illness in J&J's Phase III COVID-19 vaccine trial, the firm said during its third quarter financial call.